Analyst Research Report Snapshot

Title:

Griffin Securities updates coverage of Celsion Corp (CLSN)

Price:

$127.00

Provider:

Griffin Securities, Inc.

Date:

04 Oct 2013

Pages:

13

Type:

AcrobatPDF

Companies referenced:

CLSN.OQ

Available for Immediate Download
Summary:

Overall survival benefit with Celsion's ThermoDox is nearing significance. Data from the HEAT Study and from recent investigations of primary liver cancer may set the stage for a pivotal Phase 3 trial in 2014.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.